Analyst consensus rating
Cellectis Analyst Rating: Buy
CLLS is rated Buy by 5 analysts with a $7.60 target. As of 2026-08-24.
Direct answer
Cellectis's consensus rating is Buy.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $7.60.
Forecast evidence checked August 24, 2026.
Get free Cellectis email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $3.19
- Average price target
- $7.60
- High price target
- $10.00
- Low price target
- $4.00
- Low target gap
- +25.4%
- Target upside
- +138.2%
- High target gap
- +213.5%
- Target range width
- 188.1%
- Consensus rating
- Buy
- Analysts
- 5
- Evidence date
- August 24, 2026
- Valid through
- August 31, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Cellectis?
Cellectis has a verified Buy consensus. The same dataset has an average price target of $7.60.
How far are Cellectis's low and high targets from the recorded price?
The low target implies +25.4%, while the high target implies +213.5%.
How many analysts are included in Cellectis's consensus?
The verified consensus includes 5 analysts.
How is Cellectis's target upside or downside calculated?
The average target of $7.60 is divided by the recorded price of $3.19, then one is subtracted to produce +138.2%. This does not guarantee a future return.
When was Cellectis's analyst forecast verified?
The data was verified on 2026-08-24. The dataset is valid through 2026-08-31.